Description
UK #1 Tirzepatide Source
✓ In Stock
48hr UK Dispatch
COA Included
Cold-Chain Delivery
Dual GLP-1/GIP Agonist
Research Use Only
The Alluvi Tirzepatide 40mg is the UK’s most trusted Synedica Tirzepatide pen — a pre-filled, Synedica-manufactured, research-grade subcutaneous injection pen containing 40mg of dual GLP-1/GIP receptor agonist tirzepatide. As the definitive intermediate-phase research compound in Alluvi Healthcare’s Synedica range, the Alluvi Tirzepatide 40mg bridges the gap between single-agonist semaglutide research and full triple-agonist Alluvi Retatrutide protocols — making it the ideal compound for comparative metabolic pathway research, intermediate-phase studies, and researchers building towards the full retatrutide pen UK programme. Independently verified at ≥98% purity, batch COA included, cold-chain dispatched from UK stock within 48 hours. For research and educational purposes only. Not for human or veterinary consumption.
What Is the Alluvi Tirzepatide 40mg?
The Alluvi Tirzepatide 40mg is a pre-filled, Synedica-manufactured, research-grade injection pen containing 40mg of tirzepatide — a dual GLP-1/GIP receptor agonist peptide and one of the most extensively studied metabolic research compounds available in the UK today. Supplied exclusively by Alluvi Healthcare as part of the Synedica range, the Alluvi Tirzepatide 40mg represents the essential intermediate step in any comprehensive metabolic research programme — positioned between single-agonist semaglutide research and the full triple-agonist Alluvi Retatrutide 40mg Pen.
Synedica Tirzepatide simultaneously activates two key hormone receptor pathways — GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) — in a single molecule. This dual-agonist architecture delivers significantly enhanced metabolic research outcomes compared to single-agonist GLP-1 compounds, while providing a direct pharmacological comparison baseline for researchers studying the incremental effects of adding glucagon receptor agonism in the transition to Alluvi Retatrutide.
When UK researchers search for Synedica Tirzepatide, look to buy retatrutide UK alongside a dual-agonist comparator, or need a trusted UK retatrutide UK source for the full compound range — Alluvi Healthcare at buyalluvipeptides.co.uk is the answer.
What’s Included — Alluvi Tirzepatide 40mg Research Kit
Every Alluvi Tirzepatide 40mg order from Alluvi Healthcare is dispatched as a complete research kit from UK stock in discreet, cold-chain insulated, unmarked outer packaging. Everything you need to begin a tirzepatide research protocol immediately upon receipt:
- 1 × Pre-filled Alluvi Tirzepatide 40mg Pen — Synedica manufactured, precision click-dial mechanism, subcutaneous injection format
- 12 × Sterile single-use disposable pen needles — compatible with the Alluvi Synedica pen format
- 1 × Batch-specific Certificate of Analysis (COA) — independent third-party purity verification confirming ≥98% tirzepatide
- 1 × Alluvi Research Information Sheet — compound overview, dosage protocol reference, storage and handling guidance
- Cold-pack insulated thermal liner — maintains 2–8°C throughout UK transit
- Discreet unmarked outer packaging — no brand name or product indicators on the outer box
- Full tracked delivery label — Royal Mail / DPD tracking from dispatch to delivery
Full Technical Specifications — Alluvi Tirzepatide 40mg
The following specifications apply to every Alluvi Tirzepatide 40mg pen supplied by Alluvi Healthcare. All Synedica Tirzepatide units are manufactured under controlled pharmaceutical conditions and independently verified before UK supply.
| Product Name | Alluvi Tirzepatide 40mg (Synedica) |
| Manufacturer | Synedica (distributed by Alluvi Healthcare UK) |
| Active Compound | Tirzepatide |
| Compound Class | Dual GLP-1 / GIP Receptor Agonist |
| Total Tirzepatide Per Pen | 40mg |
| Dosage Increments | 2.5mg · 5mg · 7.5mg · 10mg (precision click-dial) |
| Maximum Full Doses Per Pen | 4 × 10mg doses |
| Maximum Micro-Doses Per Pen | Up to 16 × 2.5mg increments |
| Delivery Format | Pre-filled subcutaneous injection pen |
| Needle Type | Fine-gauge subcutaneous pen needle (12 included) |
| Purity Standard | ≥98% (independent third-party lab verification) |
| Certificate of Analysis | Batch-specific COA included with every order |
| Storage — Unopened | Refrigerated 2–8°C, away from direct light. Do not freeze. |
| Storage — In Use | Room temperature <30°C for up to 28 days, or return to refrigeration |
| Shelf Life | 24 months from date of manufacture (see pen label) |
| Receptor Targets | GLP-1 Receptor · GIP Receptor |
| Ideal Research Context | Intermediate protocols · Dual-vs-triple agonist comparison · Transition to retatrutide |
| Research Use Only | Not for human or veterinary consumption |
| UK Dispatch Time | Within 48 hours of order confirmation |
| UK Delivery | 1–2 working days from dispatch, fully tracked |
| Packaging | Cold-chain insulated, discreet unmarked outer box |
| Supplier | Alluvi Healthcare — buyalluvipeptides.co.uk |
The Science — What Is Tirzepatide & How Does the Dual Agonist Mechanism Work?
Tirzepatide is a synthetic dual agonist peptide that simultaneously activates two critical hormone receptor pathways — GLP-1 and GIP — in a single molecule. Originally developed by Eli Lilly and Company under the brand name Mounjaro, tirzepatide represented a landmark advance in metabolic research peptide design when Phase 3 trial data was published, demonstrating outcomes that significantly outperformed all prior single-agonist GLP-1 compounds. The Alluvi Tirzepatide 40mg from Synedica brings this compound to UK researchers in a pharmaceutical-grade, pre-filled pen format.
The Two Receptor Pathways in Alluvi Tirzepatide 40mg
Glucagon-like peptide-1 (GLP-1) receptor activation suppresses appetite signalling in the hypothalamus, slows gastric emptying to prolong satiety, enhances glucose-stimulated insulin secretion, and improves glycaemic control. In the Alluvi Tirzepatide 40mg, the GLP-1 agonist component is structurally optimised for greater receptor engagement than first-generation GLP-1 compounds, delivering a more potent appetite-suppression signal profile from the very first dose of an initiation-phase protocol.
Glucose-dependent insulinotropic polypeptide (GIP) receptor activation is the mechanism that fundamentally distinguishes Synedica Tirzepatide from semaglutide and all single-agonist GLP-1 compounds. GIP agonism supports insulin release in a glucose-dependent manner, enhances peripheral fat metabolism in synergy with GLP-1 signalling, improves insulin sensitivity in adipose and muscle tissue, and contributes to overall energy balance regulation. The combined GLP-1 + GIP dual activation in the Alluvi Tirzepatide 40mg creates a uniquely powerful dual metabolic research platform that no single-agonist compound can replicate.
Why the Dual-Agonist Platform Matters for UK Researchers
The addition of GIP agonism to the GLP-1 mechanism in Synedica Tirzepatide produces a synergistic metabolic effect that goes significantly beyond simple additive pharmacology. Research published in The New England Journal of Medicine and replicated in subsequent peer-reviewed studies demonstrated that the dual GLP-1/GIP pathway produced outcomes consistently superior to the most potent GLP-1 single-agonist comparators studied at equivalent doses.
For UK researchers using the Alluvi Tirzepatide 40mg as a comparator baseline for Alluvi Retatrutide studies, the dual-agonist data generated with the tirzepatide pen provides the critical reference point for quantifying the incremental contribution of glucagon receptor activation — the third pathway present in retatrutide but absent from tirzepatide. This makes the Alluvi Tirzepatide 40mg not just a standalone research compound but a scientifically essential component of any comprehensive triple-agonist research programme.
Alluvi Tirzepatide 40mg in Your Research Programme — Where It Fits
Understanding where the Alluvi Tirzepatide 40mg fits within a comprehensive metabolic research programme is critical for UK researchers designing multi-compound protocols. The Synedica Tirzepatide pen occupies a unique and indispensable position in the Alluvi Healthcare research range — as the intermediate dual-agonist reference compound that connects single-agonist semaglutide research to full triple-agonist Alluvi Retatrutide studies.
Three Key Research Applications for Alluvi Tirzepatide 40mg
- Standalone dual-agonist metabolic research: The Alluvi Tirzepatide 40mg is a complete research compound in its own right. For researchers studying GLP-1/GIP dual-pathway metabolic effects — appetite regulation, insulin sensitivity, energy balance, and glycaemic control — the Synedica Tirzepatide pen provides all the data required for a comprehensive standalone dual-agonist research programme.
- Comparative dual-vs-triple agonist studies: The most scientifically productive use of the Alluvi Tirzepatide 40mg is in paired comparison studies alongside the Alluvi Retatrutide 40mg Pen. By running parallel protocols with both compounds at equivalent doses, researchers can precisely quantify the incremental metabolic effect of adding glucagon receptor agonism to the dual GLP-1/GIP platform — generating novel data on the third pathway’s independent contribution to energy expenditure, lipolysis, and metabolic rate.
- Progression baseline for retatrutide programmes: For researchers beginning a multi-phase programme leading to Alluvi Retatrutide, the Alluvi Tirzepatide 40mg generates the dual-agonist baseline data that gives retatrutide findings their most meaningful scientific context. Without a tirzepatide baseline, the glucagon receptor contribution in retatrutide research cannot be precisely isolated or quantified.
Phase 2 (Parallel or Sequential): Alluvi Tirzepatide 40mg — dual-agonist reference data for GLP-1/GIP pathway mapping.
Phase 3–4 (Weeks 9 onwards): Alluvi Retatrutide 40mg Pen — advanced triple-agonist maintenance data with tirzepatide as the dual-agonist comparator baseline.
All three compounds are UK-stocked and available from Alluvi Healthcare.
Research Dosage Protocol Reference — Alluvi Tirzepatide 40mg
The following dosage schedule reflects the staged escalation protocols documented in peer-reviewed tirzepatide research including the SURPASS trial series. This is provided as scientific and educational reference only — not medical advice. The Alluvi Tirzepatide 40mg is for laboratory research use only and is not for human consumption.
| Research Phase | Weeks | Reference Dose | Doses From 40mg Pen | Research Notes |
|---|---|---|---|---|
| Phase 1 — Initiation | 1–4 | 2.5mg | 16 doses | Baseline dual-agonist response; GLP-1/GIP receptor engagement mapping |
| Phase 2 — Titration I | 5–8 | 5mg | 8 doses | First escalation; GIP synergy with GLP-1 becomes measurable |
| Phase 3 — Titration II | 9–12 | 7.5mg | 5–6 doses | Mid-range escalation; dual-agonist peak synergy documentation |
| Phase 4 — Maintenance | 13–72+ | 10mg | 4 doses per pen | Full-dose maintenance; consistent with SURPASS trial protocol endpoints |
The Alluvi Tirzepatide 40mg pen’s click-dial mechanism supports all four protocol phases from a single pen at 10mg weekly dosing (4 weeks per pen at maximum dose). For researchers running parallel tirzepatide and retatrutide pens UK comparison studies, maintaining equivalent dosing phases between both compounds is essential for scientifically valid comparative data.
Alluvi Tirzepatide 40mg vs Alluvi Retatrutide 40mg vs Retatrutide 20mg UK — Full Comparison
For UK researchers evaluating the full Alluvi Healthcare compound range, the following comparison table provides a direct overview of the Alluvi Tirzepatide 40mg alongside the Alluvi Retatrutide 40mg Pen and Alluvi Retatrutide 20mg Pen.
| Feature | Alluvi Tirzepatide 40mg | Alluvi Retatrutide 40mg Pen | Alluvi Retatrutide 20mg Pen |
|---|---|---|---|
| GLP-1 Agonism | ✓ Yes | ✓ Yes | ✓ Yes |
| GIP Agonism | ✓ Yes | ✓ Yes | ✓ Yes |
| Glucagon Agonism | ✗ No | ✓ Yes | ✓ Yes |
| Receptor Targets | Dual Agonist | Triple Agonist | Triple Agonist |
| Total Compound Per Pen | 40mg | 40mg | 20mg |
| Full 10mg Doses | 4 doses | 4 doses | 2 doses |
| Manufacturer | Synedica | Synedica | Synedica |
| COA Included | ✓ Every order | ✓ Every order | ✓ Every order |
| Best Research Use | Dual-agonist studies · Retatrutide comparator baseline | Advanced · Maintenance · Triple-agonist | Initiation · Pilot studies |
| UK Stock | ✓ In Stock | ✓ In Stock | ✓ In Stock |
| Buy From | buyalluvipeptides.co.uk | buyalluvipeptides.co.uk | buyalluvipeptides.co.uk |
The key differentiator between the Alluvi Tirzepatide 40mg and the Alluvi Retatrutide range is the absence of glucagon receptor agonism in tirzepatide. This makes tirzepatide the scientifically perfect comparator compound for isolating the glucagon pathway’s contribution in retatrutide research — one of the most valuable and publishable data points in UK metabolic peptide research today.
How to Use the Alluvi Tirzepatide 40mg Pen — Step-by-Step Research Protocol
The Alluvi Tirzepatide 40mg pen is pre-filled and ready to use immediately — no mixing, no reconstitution, and no preparation required beyond standard laboratory hygiene protocols. The precision click-dial mechanism ensures consistent, repeatable dosing across all research sessions.
- Remove from refrigeration: Take the Alluvi Tirzepatide 40mg pen from the refrigerator 15–30 minutes before use. Allow it to reach ambient room temperature naturally — do not heat artificially. This ensures optimal compound viscosity and consistent flow during injection.
- Visual inspection: Inspect the pen through the clear window. The tirzepatide solution should appear clear to slightly opalescent and completely free of visible particles or discolouration. If the solution appears cloudy or if the pen has been frozen, do not use — contact Alluvi Healthcare on +44 7537 823566 immediately.
- Attach a sterile needle: Select a fresh sterile needle from the 12-pack included with your kit. Remove the outer protective seal. Screw clockwise firmly onto the pen tip until fully secure. Use a new, sterile needle for every research session — never reuse.
- Prime the pen: Select a small prime amount on the dose dial. Hold the pen upright with the needle pointing upward and press the injection button fully to expel any trapped air bubbles. A drop of solution at the needle tip confirms successful priming and clear flow.
- Set research dose: Rotate the click-dial to the required research dose — 2.5mg, 5mg, 7.5mg, or 10mg depending on your protocol phase. Confirm the selected dose is clearly and correctly displayed in the dose window before proceeding to injection.
- Select injection site: Choose an appropriate subcutaneous injection site — the periumbilical abdomen (minimum 5cm from the navel), the anterolateral thigh, or the posterior upper arm. Rotate sites systematically between sessions to minimise localised tissue response. Clean the site with an alcohol swab and allow to dry completely before injection.
- Administer: Hold the pen at a 90-degree angle to the skin surface. Insert the needle with a smooth, controlled motion. Press the injection button fully downward and hold for a full 5–10 second count before withdrawing — this ensures the complete dose is delivered without backflow.
- Post-injection protocol: Remove the used needle immediately and dispose in a certified sharps container. Replace the pen cap. Record the dose, date, injection site, and any observations in your research log. Return the Alluvi Tirzepatide 40mg pen to refrigerated storage (2–8°C) promptly.
Storage & Handling — Alluvi Tirzepatide 40mg
Proper storage of the Alluvi Tirzepatide 40mg is essential to preserving compound purity, structural integrity, and research validity. Tirzepatide, like all synthetic peptide research compounds, is sensitive to temperature extremes and light exposure. Alluvi Healthcare cold-chain dispatches every order — but researcher storage responsibility begins upon receipt.
- Unopened storage: Refrigerate at 2–8°C immediately upon receipt. Store upright in original packaging. Protect from direct light at all times. Shelf life up to 24 months from manufacture date (printed on pen label).
- In-use storage: An opened Alluvi Tirzepatide 40mg pen may be stored at room temperature (maximum 30°C) for up to 28 days in a controlled research setting. Mark the first-use date clearly on the pen barrel. Return to refrigeration between sessions wherever possible.
- Never freeze: Freezing will permanently and irreversibly denature the tirzepatide peptide structure. A frozen pen is compromised and must be discarded — it cannot be recovered. If you suspect the pen was frozen during transit, do not use — contact Alluvi Healthcare immediately.
- Light protection: UV and sustained fluorescent light exposure degrades the tirzepatide compound over time. Always store the pen with its cap secured and away from direct sunlight, laboratory UV sources, and open windows.
- Transport: Use an insulated carrier with a pharmaceutical cold pack to maintain 2–8°C when transporting the Alluvi Tirzepatide 40mg between research sites. Do not transport without cold-chain protection.
- Disposal: Expired or depleted Alluvi Tirzepatide 40mg pens should be disposed via your institution’s pharmaceutical research waste contractor, in compliance with applicable UK chemical waste regulations.
Why Buy Alluvi Tirzepatide 40mg from Alluvi Healthcare — The UK’s Most Trusted Synedica Source
When UK researchers look to source Synedica Tirzepatide alongside the Alluvi Retatrutide range, supplier quality is non-negotiable. Here is why Alluvi Healthcare is the UK’s definitive source for the Alluvi Tirzepatide 40mg and the complete Synedica research compound range.
- Synedica-Manufactured & Independently Verified: The Alluvi Tirzepatide 40mg is manufactured by Synedica — the same manufacturer behind our Alluvi Retatrutide 40mg Pen and Alluvi Retatrutide 20mg Pen. Every batch is independently tested and COA-verified at ≥98% purity. Included automatically with every order.
- 100% UK-Based Stock: Alluvi Healthcare holds genuine UK inventory of the Synedica Tirzepatide pen. No overseas imports, no customs complications, no cold-chain breaches from international shipping. Your Alluvi Tirzepatide 40mg is in the UK before you order it.
- Guaranteed 48-Hour UK Dispatch: Every Alluvi Tirzepatide 40mg order is dispatched within 48 hours of order confirmation via fully tracked, cold-chain Royal Mail or DPD delivery. Most UK orders arrive within 1–2 working days of dispatch.
- Expert UK Research Support: Our research support team understands the full Synedica compound range — tirzepatide, retatrutide 20mg and 40mg, and the comparative research protocols that connect them. Call us Monday to Saturday: +44 7537 823566.
- Competitive & Transparent Pricing: Alluvi Healthcare’s Synedica Tirzepatide pricing is competitive against all UK market alternatives, with no hidden charges and free tracked UK delivery on orders over £150.
- Complete Discretion Guaranteed: Every order dispatched in plain, unmarked outer packaging — no brand identification, no product indication visible from the exterior. Fully tracked and insured.
- One-Stop Synedica Research Supply: Alluvi Healthcare is the only UK supplier where you can order the complete Synedica research range — Alluvi Tirzepatide 40mg, Alluvi Retatrutide 40mg Pen, Alluvi Retatrutide 20mg Pen, Supplement Box, and Gummy Range — from a single trusted UK source.
- Wholesale & Bulk Pricing: Research institutions and high-volume buyers can access competitive bulk pricing on Synedica Tirzepatide and the full Alluvi range. Contact us via buyalluvipeptides.co.uk/contact or call +44 7537 823566.
Synedica Tirzepatide UK — Understanding the Market & Finding a Trusted Source
The UK research peptide market has grown significantly over the past two years, and demand for Synedica Tirzepatide — particularly alongside retatrutide pens UK — has never been higher. However, the quality, authenticity, and cold-chain compliance of tirzepatide suppliers in the UK varies enormously. Here is what every UK researcher needs to know before purchasing Synedica Tirzepatide from any source.
Key Criteria for a Trusted Synedica Tirzepatide UK Supplier
- Named pharmaceutical manufacturer: The Alluvi Tirzepatide 40mg is manufactured by Synedica — a named, verifiable pharmaceutical manufacturer. Any supplier who cannot or will not name the manufacturer of their tirzepatide compound should be avoided immediately.
- Batch-specific COA as standard: A Certificate of Analysis that is batch-specific — linking purity results to the exact batch in your pen — is the minimum acceptable standard. Generic, undated, or non-batch-specific COAs are not equivalent. Alluvi Healthcare provides batch-specific COAs automatically with every order.
- Genuine UK inventory: UK-based stock means 48-hour dispatch and no cold-chain temperature breach from overseas transit. Alluvi Healthcare physically holds Synedica Tirzepatide stock in the UK.
- Cold-chain dispatch as standard: Tirzepatide is as temperature-sensitive as retatrutide — it must be cold-chain dispatched. Any supplier dispatching without insulated cold-pack packaging is compromising your compound before it reaches you.
- UK-based, knowledgeable support: A real phone number, answered by people who understand the science. +44 7537 823566 — Monday to Saturday, Alluvi Healthcare.
- Research-only compliance: UK suppliers of Synedica Tirzepatide must clearly position all products as research compounds only. Suppliers making therapeutic or medical claims are operating outside UK regulatory guidelines.
The Full Alluvi Healthcare Research Range — Synedica UK
The Alluvi Tirzepatide 40mg is one of three core Synedica research compounds available exclusively from Alluvi Healthcare in the UK. Together, the Alluvi range gives researchers everything needed for a comprehensive, multi-compound, multi-phase metabolic research programme.
💉
Verified UK Researcher Reviews — Alluvi Tirzepatide 40mg
The following reviews are from verified UK researchers who have purchased the Alluvi Tirzepatide 40mg from Alluvi Healthcare. All reviews relate to product quality, delivery, and research experience — not medical outcomes.
“Running a parallel tirzepatide vs retatrutide study and Alluvi Healthcare is the only UK source I trust for both. The Synedica Tirzepatide 40mg arrived cold, COA confirmed ≥98%, and the click mechanism is precise. Exactly what a comparison study needs.”
“Best place to source Synedica Tirzepatide in the UK, full stop. Ordered Tuesday, arrived Wednesday cold and intact. The COA was batch-specific and detailed. Alluvi Healthcare is our permanent UK Synedica source for both tirzepatide and the retatrutide pens UK.”
“Using the Alluvi Tirzepatide 40mg as a comparator baseline alongside the Alluvi Retatrutide 40mg pen. Batch-to-batch consistency is exceptional — critical for comparative data integrity. Alluvi Healthcare is the only UK source that delivers this level of quality.”
“Switched to Alluvi from another Synedica Tirzepatide UK source after COA inconsistencies elsewhere. Alluvi Healthcare is in a completely different league — proper cold-chain packaging, real batch COA, and a support team that actually understands the science.”
“Ordered the Alluvi Tirzepatide 40mg alongside the retatrutide 20mg UK pen for a structured 16-week initiation study. Both arrived next day, both cold, both with batch COAs. The research information sheets were genuinely useful for protocol design.”
“We order 8–10 Synedica Tirzepatide and retatrutide pens per month from Alluvi Healthcare. Never had a single issue with quality, cold chain, or dispatch timing. The wholesale pricing is competitive and the support team is responsive. Permanent UK source.”
Research References — Scientific & Regulatory Context for the Alluvi Tirzepatide 40mg
The following authoritative external resources provide the scientific and regulatory context relevant to the Alluvi Tirzepatide 40mg and tirzepatide research in the United Kingdom. All provided for educational reference purposes only.
🔬
Frequently Asked Questions — Alluvi Tirzepatide 40mg
The Alluvi Tirzepatide 40mg is a pre-filled, Synedica-manufactured, research-grade subcutaneous injection pen containing 40mg of tirzepatide — a dual GLP-1/GIP receptor agonist peptide. Supplied exclusively in the UK by Alluvi Healthcare for laboratory research and development purposes only. Not for human or veterinary consumption.
Synedica Tirzepatide is the pharmaceutical-grade tirzepatide formulation manufactured by Synedica — the same manufacturer behind the Alluvi Retatrutide 40mg Pen and Alluvi Retatrutide 20mg Pen. The Alluvi Tirzepatide 40mg is the UK distribution of this Synedica-manufactured compound, supplied exclusively by Alluvi Healthcare at buyalluvipeptides.co.uk.
The key difference is the number of receptor pathways activated. Alluvi Tirzepatide 40mg is a dual agonist — activating GLP-1 and GIP receptors. The Alluvi Retatrutide range is a triple agonist — activating GLP-1, GIP, and Glucagon receptors simultaneously. Tirzepatide is the scientifically ideal comparator compound for quantifying the glucagon receptor’s independent contribution in retatrutide research.
The Alluvi Tirzepatide 40mg (Synedica Tirzepatide) is available exclusively from Alluvi Healthcare at buyalluvipeptides.co.uk — the UK’s most trusted Synedica research compound source. UK-stocked, 48hr dispatch, cold-chain tracked delivery, COA included. Call our research support team: +44 7537 823566.
Yes — and this is actually the most scientifically productive way to use the Alluvi Tirzepatide 40mg. Running parallel or sequential protocols with tirzepatide and the Alluvi Retatrutide range allows researchers to precisely quantify the glucagon receptor’s independent contribution to metabolic outcomes — one of the most valuable data points in current metabolic peptide research. All three compounds are UK-stocked at Alluvi Healthcare.
All Alluvi Tirzepatide 40mg orders are dispatched from UK stock within 48 hours of order confirmation via tracked cold-chain delivery (Royal Mail or DPD). Most UK orders arrive within 1–2 working days from dispatch. A full tracking number is provided by email upon dispatch.
Yes. Every Alluvi Tirzepatide 40mg order includes a batch-specific Certificate of Analysis (COA) from independent third-party testing, confirming tirzepatide purity at ≥98%. The COA is included automatically with every order — no request required.
Store refrigerated at 2–8°C immediately upon receipt. Do not freeze under any circumstances. Protect from direct light. Unopened shelf life is up to 24 months from manufacture date. Once opened, the pen may be kept at room temperature (below 30°C) for up to 28 days, or returned to refrigeration between research sessions.
No. The Alluvi Tirzepatide 40mg is a research-grade Synedica-manufactured tirzepatide compound supplied for laboratory research purposes only. Mounjaro is a licensed pharmaceutical medicine approved for prescription use in the UK. The Alluvi Tirzepatide 40mg is not a licensed medicine, is not available on prescription, and is not for human consumption. It is supplied strictly as a research compound by Alluvi Healthcare for laboratory use only.
Yes. Alluvi Healthcare offers competitive wholesale and institutional bulk pricing on the Alluvi Tirzepatide 40mg and the full Synedica range. Contact us via buyalluvipeptides.co.uk/contact or call +44 7537 823566 to discuss your volume requirements and receive a wholesale pricing quote.
Explore More from Alluvi Healthcare
🏠
Reviews
There are no reviews yet.